clinical trial · NCT06602258
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
Alzheimer's DiseaseE2814LecanemabPlacebo
brief summary
The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 6 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's disease (AD).
started
Sep 30, 2024
primary completion
Dec 3, 2026
completion
Aug 18, 2027
last updated
Feb 11, 2026
official title
A Phase 2, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Study to Evaluate Safety, Tolerability, and Biomarker Efficacy of E2814 With Concurrent Lecanemab Treatment in Subjects With Early Alzheimer's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol